As more of these novel—and costly—cell therapies gain approval, revamped strategies around scaling, coordination and workflow are critical to their launch
Joel Wayment, Cardinal Health 3PL Services
Advertisement
Articles by Joel Wayment, Cardinal Health 3PL Services
Advertisement
Latest Updated Articles
3PL Outsourcing Models: Which is best for your business?Published: November 5th 2019 | Updated:
CAR-T Therapies: Three Supply Chain ConsiderationsPublished: February 10th 2022 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
Pharma Pulse: Novartis Buys Avidity for $12B, and Trump Threatens 10% Tariff Hike on Canada
2
Trump Threatens 10% Tariff Hike on Canadian Imports After Controversial Reagan Ad Airs During World Series
3
LogiPharma USA 2025: Pharma Supply Chains Evolve Toward Real-Time Visibility and End-to-End Control
4
Why DTC Drug Models Must Evolve From Access to True Patient Support
5
